Dr. Borghaei on Selecting Single-Agent Versus Combination Therapy in Lung Cancer

Video

Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses selecting between single-agent versus combination therapeutic approaches in lung cancer.

Single-agent therapies that are supported by clinical data are recommended for patients who are likely to achieve disease control with 1 drug, Borghaei says. Approved chemoimmunotherapy or immunotherapy combinations have demonstrated manageable safety profiles and should be considered in appropriate patients, Borghaei explains. Currently, PD-L1 expression can be used to inform which patients should receive combination regimens; however, additional biomarkers are needed, concludes Borghaei.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center